Find and Pitch Jounalists, Get Your Story Covered

Tags: leukemia cancer acute promyelocytic leukemia bone marrow biopsy fever

	Profile	Recent Articles on Subject
1	<em>The Scientist</em> The Scientist Exploring Life, Inspiring Innovation. scienceinnovation	What Drives Myeloid Cell Responses to Disease - 7 days ago
2	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	STAT+: For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission - 11 days ago STAT+: A targeted therapy shows it can offer a ‘last, great chance’ for some acute leukemia patients - about 1 year ago
3	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More - 12 days ago
4	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis - 14 days ago Arcellx to present positive data on multiple myeloma treatments - about 2 months ago
5	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	Study paints clearer picture of disadvantaged leukemia patients’ struggle to get bone marrow transplants - 16 days ago
6	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL - 17 days ago FDA Approves Earlier Use of CAR-T Products for Myeloma - 9 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - about 1 year ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - about 1 year ago MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia - about 1 year ago Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials - about 1 year ago Completely Oral Regimen Effective, Feasible in APL - about 1 year ago
7	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	FDA Investigating Blood Cancer Risk With Gene Therapy Skysona - 27 days ago
8	Amir Ali, PharmD, BCOP Pharmacy Times Clinical Hem/Onc Pharmacist. USC Assistant Professor. Founder of OncologySolutionsRx. Los Angeles, CA Healthcareoncologypharmacyeducation	Final Thoughts - about 1 month ago Impact of Transplant Eligibility on Treatment Selection - 3 months ago
9	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - about 2 months ago
10	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma - 2 months ago AI Model Can Differentiate Prefibrotic Primary Myelofibrosis From Essential Thrombocythemia With High Accuracy - about 1 year ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - about 1 year ago Prenatal Folate May Program Hematopoietic Stem Cell Function Into Adulthood - about 1 year ago

Journalists covering myeloid leukemia